Colorectal cancer chemotherapy: the evolution of treatment and new approaches
RM McQuade, V Stojanovska… - Current medicinal …, 2017 - ingentaconnect.com
Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality.
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket
A Donnelly, BSJ Blagg - Current medicinal chemistry, 2008 - ingentaconnect.com
The 90 kDa heat shock proteins (Hsp90), which are integrally involved in cell signaling,
proliferation, and survival, are ubiquitously expressed in cells. Many proteins in tumor cells …
proliferation, and survival, are ubiquitously expressed in cells. Many proteins in tumor cells …
A review on oxaliplatin-induced peripheral nerve damage
AA Argyriou, P Polychronopoulos, G Iconomou… - Cancer treatment …, 2008 - Elsevier
Platinum compounds are a class of chemotherapy agents that posses a broad spectrum of
activity against several solid malignancies. Oxaliplatin (OXL) is a third-generation …
activity against several solid malignancies. Oxaliplatin (OXL) is a third-generation …
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
AV Khrunin, A Moisseev, V Gorbunova… - The pharmacogenomics …, 2010 - nature.com
Platinum drugs are among the most active and widely used agents in the treatment of
different cancers. However, the great individual variability in both outcome and toxicity of …
different cancers. However, the great individual variability in both outcome and toxicity of …
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer
KJ Cullen, Z Yang, L Schumaker, Z Guo - Journal of bioenergetics and …, 2007 - Springer
Cisplatin is among the most important chemotherapeutic agents ever developed. It is a
critical component of therapeutic regimens in a broad range of malignancies. However …
critical component of therapeutic regimens in a broad range of malignancies. However …
3-Bromopyruvate: targets and outcomes
MC Shoshan - Journal of bioenergetics and biomembranes, 2012 - Springer
Abstract The pyruvate mimetic 3-bromopyruvate (3-BP) is generally presented as an
inhibitor of glycolysis and has shown remarkable efficacy in not only preventing tumor …
inhibitor of glycolysis and has shown remarkable efficacy in not only preventing tumor …
Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
D Buac, S Schmitt, G Ventro… - Mini reviews in …, 2012 - ingentaconnect.com
Dithiocarbamates are a class of metal-chelating compounds with various applications in
medicine. They have been used for the treatment of bacterial and fungal infections, possible …
medicine. They have been used for the treatment of bacterial and fungal infections, possible …
Role of oxidative stress in oxaliplatin‐induced enteric neuropathy and colonic dysmotility in mice
RM McQuade, SE Carbone… - British journal of …, 2016 - Wiley Online Library
Background and Purpose Oxaliplatin is a platinum‐based chemotherapeutic drug used as a
first‐line therapy for colorectal cancer. However, its use is associated with severe …
first‐line therapy for colorectal cancer. However, its use is associated with severe …
Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer
L Moyano‐Galceran, EA Pietilä, SP Turunen… - EMBO molecular …, 2020 - embopress.org
Metastatic cancers commonly activate adaptive chemotherapy resistance, attributed to both
microenvironment‐dependent phenotypic plasticity and genetic characteristics of cancer …
microenvironment‐dependent phenotypic plasticity and genetic characteristics of cancer …
[HTML][HTML] Comparison of oxaliplatin-and cisplatin-induced painful peripheral neuropathy in the rat
EK Joseph, JD Levine - The Journal of Pain, 2009 - Elsevier
Although platinum-based cancer chemotherapies produce painful peripheral neuropathy as
dose-limiting side effects, there are important differences in the pain syndromes produced by …
dose-limiting side effects, there are important differences in the pain syndromes produced by …